Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- New Detailing Guidelines Go into Full Effect on October 1, Making Supervisory Systems Mandatory
October 1, 2019
- MHLW Panel Members Call for Discussion on Range of Health Coverage
September 30, 2019
- Rotavirus Vaccines Added to Public Vaccination Programs from Oct. 1, 2020: MHLW Panel
September 30, 2019
- Chuikyo Supports Earlier Price Cuts for Certain Off-Patent Brand-Name Drugs
September 26, 2019
- MHLW Orders Label Revisions for Actemra, Tagrisso, Olumiant and More
September 25, 2019
- Intussusception Cases within 21 Days after Rotavirus Vaccination Should Be Reported: MHLW Panels
September 25, 2019
- Japan Launches Panel to Discuss “Social Security for All Generations”
September 24, 2019
- Japan Approves Astellas’ HIF-PH Inhibitor, AbbVie’s Venclexta, Tecentriq’s Breast Cancer Use and More
September 24, 2019
- Japan Clears First Biosimilars for Nesp and Forteo, Second Rituxan, Avastin Follow-Ons Too
September 24, 2019
- MHLW Asks 15 Makers to Investigate Ranitidine, Nizatidine for Potential Carcinogen Contamination
September 20, 2019
- Sakigake Status Withdrawn for Aducanumab: MHLW
September 20, 2019
- Kobe Univ. Received Pilot Certification as APEC Training Center of Excellence
September 20, 2019
- Doctor, Payer Reps Stress Need for More Education about Biosimilars Before Introducing Premium for Their Use: Chuikyo
September 19, 2019
- MHLW Panel Backs Inclusion of Rotavirus Vaccines to Public Immunization Program
September 17, 2019
- Orphan Status Granted to Satralizumab, 2 Other Drugs
September 17, 2019
- Show Us Concrete Proposals for Drug Pricing Reform: Kyokai Kenpo Director to Pharma
September 13, 2019
- Chuikyo Agrees on Need to Look at More Examples to Craft Pricing Models for Cell & Gene Therapies
September 12, 2019
- Both Payer, Doctor Members Want to Expand Comparator PMP Removal Rule, but Mixed on Timing: Chuikyo
September 12, 2019
- Chuikyo Members Open to Post-Launch Premiums for Add’l Indications, but Call for Careful Application
September 12, 2019
- 9 Topics Presented towards 2020 Pricing Reform; Industry Hearing Slated for November-December: Chuikyo
September 12, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…